Co., Inc. (NYSE:MRK), a global healthcare leader, declared on Monday a quarterly dividend and a substantial stock repurchase ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has ...

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong ...

We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to ...

Lockheed Martin’s fourth-quarter earnings per share topped expectations, while the top line disappointed. The outlook was mixed, as well.

When Merck reports fourth-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, ...

Highlights:,Merck & Co., (NYSE:MRK),, Inc. shares opened at nearly $98 on Tuesday.,The company has a market capitalization of ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $97.94 which represents a slight increase of $2.39 or 2.50% from the prior close of $95.55. The stock opened at $96.63 and touched a ...

Merck & Co. Inc. closed 27.25% short of its 52-week high of $134.63, which the company reached on June 25th.

We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at ...

These are unquestionably serious issues, but Merck remains a top stock to buy and hold, at least for investors focused on the long game. Here's why. Merck's Keytruda generates over $20 billion in ...

Merck & Co Inc (MRK) stock saw a decline, ending the day at $95.55 which represents a decrease of $-1.08 or -1.12% from the prior close of $96.63. The stock opened at $96.79 and touched a low of ...